Zhang Xue, Su Kaiyan, Liu Yifan, Zhu Darong, Pan Yuting, Ke Xisong, Qu Yi
Shanghai Frontiers Science Center for Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Department of Pharmacy, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Front Pharmacol. 2022 Jan 27;12:793449. doi: 10.3389/fphar.2021.793449. eCollection 2021.
Musashi-2 (MSI2) is an evolutionally conserved RNA-binding protein and recently considered as an attractive therapeutic target in a wide spectrum of malignancies. However, MSI2-engaged mRNAs are not well profiled, and no MSI2-dependent antagonist is available so far. In the study, we created MSI2 knockout cancer cells and demonstrated that MSI2 is required for the survival of colorectal cancer HCT116 cells but not non-small cell lung cancer A549 cells. In addition, the global profiling of the transcriptome and proteomics of MSI2 knockout colorectal cells revealed 38 candidate MSI2-targeted genes. In a loss-rescue screening, palmatine was identified as a functional MSI2 antagonist inhibiting the MSI2-dependent growth of colorectal cancer cells. Finally, we confirmed that palmatine is directly bound to MSI2 at its C-terminal. Our findings not only indicated MSI2 as a promising therapeutic target of colorectal cancer but also provided a small molecule palmatine as a direct and functional MSI2 antagonist for cancer therapy.
Musashi-2(MSI2)是一种进化上保守的RNA结合蛋白,最近被认为是多种恶性肿瘤中一个有吸引力的治疗靶点。然而,与MSI2结合的mRNA尚未得到充分分析,目前也没有MSI2依赖性拮抗剂。在本研究中,我们构建了MSI2基因敲除癌细胞,并证明MSI2是结直肠癌HCT116细胞存活所必需的,但对非小细胞肺癌A549细胞则不是必需的。此外,对MSI2基因敲除的结直肠癌细胞的转录组和蛋白质组进行全局分析,发现了38个候选的MSI2靶向基因。在一项缺失-挽救筛选中,巴马汀被鉴定为一种功能性MSI2拮抗剂,可抑制结直肠癌细胞依赖MSI2的生长。最后,我们证实巴马汀在其C末端直接与MSI2结合。我们的研究结果不仅表明MSI2是结直肠癌一个有前景的治疗靶点,还提供了一种小分子巴马汀作为癌症治疗中直接且功能性的MSI2拮抗剂。